Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Eli Lilly saw a 26% spike in call option activity, hinting that investors are feeling unusually optimistic—or just love drama ...

This rare de-escalation in the ongoing U.S.-China trade conflict and cooler inflation marked a welcome shift in tone and gave global markets room to breathe.

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Representative Jonathan L. Jackson of Illinois just made Eli Lilly his latest stock crush, scooping up $15K–$50K in shares on ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Pharma companies were mostly left out of the stock market’s broader rally Monday morning on the news that President Donald ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical ...

At March 31, 2025, the Company's cash and cash equivalents grew to $938.5 million, compared to $912.8 million at December 31, 2024, after prepaying a $50.0 million deposit related to our Evergreen ...